Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
University Hospital, Bordeaux
40 participants
Apr 5, 2024
OBSERVATIONAL
Conditions
Summary
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Eligibility
Inclusion Criteria2
- age \> 18 years
- surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Exclusion Criteria1
- systemic therapy received for non-glioblastoma tumor
Interventions
Paired tumor samples diagnosis/relapse
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06430424